Lukas  Scheibler net worth and biography

Lukas Scheibler Biography and Net Worth

Dr. Scheibler joined Apellis in April 2018 as executive vice president for research and translational medicine. In this role, he is responsible for creating and managing all preclinical research projects and advancing them into clinical development to establish proof of concept. Dr. Scheibler is an R&D professional with in-depth experience in drug development. He most recently was head of R&D at Acucela (a Seattle-based startup) and had a 13-year career in research and development, business development, and clinical development at Novartis. He holds a PhD degree from the University of Lausanne, Switzerland, and had postdoctoral training at Harvard Medical School.

What is Lukas Scheibler's net worth?

The estimated net worth of Lukas Scheibler is at least $2.74 million as of December 1st, 2023. Dr. Scheibler owns 68,299 shares of Apellis Pharmaceuticals stock worth more than $2,736,741 as of June 19th. This net worth estimate does not reflect any other investments that Dr. Scheibler may own. Learn More about Lukas Scheibler's net worth.

How do I contact Lukas Scheibler?

The corporate mailing address for Dr. Scheibler and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Lukas Scheibler's contact information.

Has Lukas Scheibler been buying or selling shares of Apellis Pharmaceuticals?

Lukas Scheibler has not been actively trading shares of Apellis Pharmaceuticals during the past quarter. Most recently, Lukas Scheibler sold 10,000 shares of the business's stock in a transaction on Friday, December 1st. The shares were sold at an average price of $60.00, for a transaction totalling $600,000.00. Following the completion of the sale, the insider now directly owns 68,299 shares of the company's stock, valued at $4,097,940. Learn More on Lukas Scheibler's trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 49 times. They sold a total of 776,863 shares worth more than $42,616,032.50. The most recent insider tranaction occured on May, 8th when insider Pascal Deschatelets sold 78,907 shares worth more than $3,341,711.45. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 5/8/2024.

Lukas Scheibler Insider Trading History at Apellis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2023Sell10,000$60.00$600,000.0068,299View SEC Filing Icon  
5/27/2022Sell10,000$43.00$430,000.0040,358View SEC Filing Icon  
4/4/2022Sell3,504$56.96$199,587.8452,233View SEC Filing Icon  
4/1/2022Sell11,496$55.05$632,854.8052,233View SEC Filing Icon  
2/11/2022Sell1,666$46.80$77,968.80View SEC Filing Icon  
2/8/2022Sell10,000$45.00$450,000.00View SEC Filing Icon  
1/31/2022Sell1,233$38.47$47,433.51View SEC Filing Icon  
6/10/2021Sell3,417$60.00$205,020.00View SEC Filing Icon  
5/24/2018Buy2,935$20.37$59,785.95View SEC Filing Icon  
See Full Table

Lukas Scheibler Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows Lukas Scheibler's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $40.07
Low: $39.53
High: $41.19

50 Day Range

MA: $44.14
Low: $39.25
High: $55.73

2 Week Range

Now: $40.07
Low: $19.83
High: $92.61


802,046 shs

Average Volume

1,032,409 shs

Market Capitalization

$4.86 billion

P/E Ratio


Dividend Yield